HUTCHMED (00013) is currently up 2.6%, trading at HK$23.80, marking its fifth consecutive day of gains with a cumulative increase of 12.5%. The stock has traded around 1.01 million shares, amounting to HK$23.91 million.
HUTCHMED announced that it has completed an overseas licensing agreement for HMPL-A830, a KRAS-EGFR antibody-drug conjugate therapy exclusively developed with a subsidiary of GlaxoSmithKline (GSK plc). The agreement grants the GSK subsidiary exclusive rights to develop and commercialize HMPL-A830 globally, excluding mainland China, Hong Kong, Macau, and Taiwan. HUTCHMED expects to receive an upfront payment of $110 million, with potential additional payments of up to $1.185 billion upon achieving regulatory, development, and commercial sales milestones, plus tiered royalties based on net sales.
According to the company, HMPL-A830 enhances efficacy, durability, and tolerability by delivering a rat sarcoma subtype KRAS inhibitor directly to tumors expressing EGFR, thereby simultaneously blocking both EGFR and KRAS signaling pathways.
Currently, a global clinical trial testing HMPL-A830 for the treatment of unresectable advanced or metastatic solid tumors in China and the United States was initiated in September 2026. (am)
HUTCHMED announced that it has completed an overseas licensing agreement for HMPL-A830, a KRAS-EGFR antibody-drug conjugate therapy exclusively developed with a subsidiary of GlaxoSmithKline (GSK plc). The agreement grants the GSK subsidiary exclusive rights to develop and commercialize HMPL-A830 globally, excluding mainland China, Hong Kong, Macau, and Taiwan. HUTCHMED expects to receive an upfront payment of $110 million, with potential additional payments of up to $1.185 billion upon achieving regulatory, development, and commercial sales milestones, plus tiered royalties based on net sales.
According to the company, HMPL-A830 enhances efficacy, durability, and tolerability by delivering a rat sarcoma subtype KRAS inhibitor directly to tumors expressing EGFR, thereby simultaneously blocking both EGFR and KRAS signaling pathways.
Currently, a global clinical trial testing HMPL-A830 for the treatment of unresectable advanced or metastatic solid tumors in China and the United States was initiated in September 2026. (am)
